Can a new drug shield lung cancer patients from Chemo's worst side effects?

NCT ID NCT06370416

ENROLLING_BY_INVITATION Disease control Sponsor: Henan Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether the drug trilaciclib, given before chemotherapy, can prevent bone marrow suppression (low blood cell counts) in people with advanced non-small cell lung cancer. About 40 participants will receive trilaciclib before their platinum-based chemo. The main goal is to see if it reduces severe neutropenia (a dangerous drop in infection-fighting white blood cells).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: trilaciclib
What this could lead to: If it works, this could point toward a way to reduce severe side effects from chemotherapy, making treatment more tolerable for lung cancer patients.
What could go wrong: This is a small, early-phase study with only 41 people and no comparison group, so results may not apply broadly. The drug may not reduce side effects as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Henan Tumor Hospital

Zhengzhou, Henan, 450000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.